Hepatitis B and C landscape in Uzbekistan: epidemiological patterns revealed in a study of 1 040 000 people.
Uzbekistan initiated a nationwide screening program for viral hepatitis B (HBV) and C (HCV) in response to the global call for viral hepatitis elimination by 2030. This study aimed to assess HBV and HCV prevalence among the general population, provide treatment for diagnosed cases, and evaluate the...
| Published in: | European Journal of Public Health Vol. 35; no. 5; pp. 1014 - 1020 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | pictorial research tables/charts Journal Article |
| Published: |
Oxford University Press / USA
Oct2025
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=188809843&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 188809843 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11011262 BHW jtl: European Journal of Public Health issn: 11011262 maglogo: N pubinfo: dt: Oct2025 vid: 35 iid: 5 pid: 622 pub: Oxford University Press / USA artinfo: ui: 188809843 188809843 188809843 10.1093/eurpub/ckaf136 188809843 ppf: 1014 ppct: 6 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Hepatitis B and C landscape in Uzbekistan: epidemiological patterns revealed in a study of 1 040 000 people. aug: au: Ismoilov, Umed Yusupovich Musabaev, Erkin Isakovich Khikmatullaeva, Aziza Saidullaevna Ibadullaeva, Nargiz Sapievna Kan, Nataliya Georgiyevna Sadirova, Shakhlo Sobirovna Bayjanov, Allabergan Kadirovich Kasimova, Rano Ibrakhimovna Juraev, Rivojiddin Khafizullaevich Mirzoeva, Mexriniso Rizoevna Yusupova, Lola Umed kizi Abdurasulov, Abdulaziz Baxtiyor ugli Khodjaeva, Malika Erkinovna Sadullaevna, Shahlo Abdulloevna Bobojonova, Oisha Shavkatovna Mirzaev, Ulugbek Khudayberdievich affil: Department of Hepatology, Research Institute of Virology, Tashkent, Uzbekistan sug: subj: Hepatitis B Epidemiology Hepatitis C Epidemiology Health Screening Hepatitis B Drug Therapy Hepatitis C Drug Therapy Antiviral Agents Therapeutic Use Drug Efficacy Treatment Outcomes Polymerase Chain Reaction Hepatitis B Diagnosis Hepatitis C Diagnosis Uzbekistan Human Male Female Infant Child, Preschool Child Adolescence Adult Middle Age Aged Aged, 80 and Over Immunoassay Chromatography Antigens, Surface Eligibility Determination Descriptive Statistics Treatment Duration Liver Cirrhosis Fibrosis Enzyme-Linked Immunosorbent Assay Chi Square Test Post Hoc Analysis T-Tests Sex Factors Age Factors Convenience Sample Funding Source Infant: 1-23 months Child, Preschool: 2-5 years Child: 6-12 years Adolescent: 13-18 years Adult: 19-44 years Middle Aged: 45-64 years Aged: 65+ years Aged, 80 & over Male Female ab: Uzbekistan initiated a nationwide screening program for viral hepatitis B (HBV) and C (HCV) in response to the global call for viral hepatitis elimination by 2030. This study aimed to assess HBV and HCV prevalence among the general population, provide treatment for diagnosed cases, and evaluate the effectiveness of direct-acting antiviral (DAA) therapy for HCV. From July 2022 to June 2024, 1 048 575 individuals aged 1-95 years were screened at local healthcare facilities using rapid immunochromatographic tests for hepatitis B surface antigen (HBsAg) and antibodies against hepatitis C virus (anti-HCV). Positive cases underwent confirmatory testing and were linked to care. HCV RNA-positive patients were assessed for DAA treatment eligibility. Overall HBsAg prevalence was 2.89% and anti-HCV prevalence was 3.52%. HBV prevalence decreased from 3.25% in those born before 2000 to 0.77% in those born after (P < .01), reflecting the impact of the national HBV vaccination program. Of 32 132 anti-HCV positive individuals, 20 039 (62.4%) were confirmed HCV RNA positive. Among these, 18 327 were eligible for DAA treatment. The majority received a 12-week treatment course, while 2126 (11%) with advanced liver fibrosis received a 24-week regimen. The sustained virological response rate was high, with only 1.17% of patients with advanced fibrosis and 0.96% without advanced fibrosis failing to achieve viral clearance. This large-scale study demonstrates the effectiveness of Uzbekistan's HBV vaccination program and the success of DAA treatment in achieving high cure rates for HCV. The study provides crucial data to guide public health strategies for combating viral hepatitis in Uzbekistan and progressing towards the World Health Organization's 2030 elimination targets. pubtype: Academic Journal doctype: pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|